Investment Rating - The report maintains a "Buy" rating for the company with a target price of $60 for the US stock and HK$47 for the Hong Kong stock [1][3]. Core Insights - The initial efficacy and safety data for ZL-1310 (DLL3 ADC) in the 2L+ ES-SCLC indication are excellent, significantly boosting investor confidence in the company's R&D pipeline [1]. - ZL-1310 demonstrated a 74% overall response rate (ORR) in the global Phase 1 trial, with a 100% ORR in patients with brain metastases [1]. - The company plans to accelerate the development of ZL-1310 for 2L+ ES-SCLC and aims to communicate with the FDA regarding the accelerated approval pathway [1]. Financial Performance - The projected revenue for 2023 is $267 million, with a year-on-year growth of 24% [2][9]. - The company is expected to incur a net loss of $335 million in 2023, improving to a loss of $137 million by 2025 [2][9]. - The revenue is forecasted to grow significantly, reaching $995 million by 2026, with a compound annual growth rate (CAGR) of 53.3% from 2023 to 2026 [2][9]. Market Expectations - The current stock price is $28.9, with a potential upside of 107% to the target price of $60 [3][5]. - The stock has a 52-week price range of $13.4 to $31.2, indicating volatility and potential for growth [3][5]. Clinical Data Comparison - ZL-1310's ORR of 74% is higher than that of competitors like YL201 (68% ORR) and ZG006 (67% ORR), showcasing its competitive edge in the market [1][8]. - The safety profile of ZL-1310 is superior, with lower rates of ≥3 grade treatment-related adverse events (TRAEs) compared to YL201 [1][8].

Investment Rating - The investment rating for the company is "Outperform the Market" [4][12]. Core Views - The company's education business performance is in line with expectations, with operational efficiency continuously improving. In FY2025Q1, education revenue increased by 34%, and net revenue reached $1.435 billion, up 30.5% year-on-year. Excluding the impact of Dongfang Zhenxuan, net revenue was $1.278 billion, up 33.5% year-on-year, aligning with the revenue guidance for FY2024Q4 [1][5]. - The company maintains a full-year capacity expansion expectation of 20-25%, with the number of schools and learning centers reaching 1,089, a 37% year-on-year increase [1][5]. - The company anticipates FY2025Q2 education revenue to grow by 25-28%, driven by strong growth in new education businesses and domestic university student training [1][5]. Summary by Relevant Sections Financial Performance - In FY2025Q1, Non-GAAP operating profit was $300 million, up 22.6% year-on-year, with a Non-GAAP operating profit margin of 20.9%. Excluding the impact of Dongfang Zhenxuan, the operating profit margin was 24%, up 2.2 percentage points year-on-year [1][5]. - Non-GAAP net profit attributable to the parent company was $265 million, up 39.85% year-on-year, exceeding Bloomberg consensus expectations [1][5]. Business Segments - The new education business showed strong growth, with overseas examination preparation and consulting businesses growing by 18.8% and 20.7% year-on-year, respectively. Domestic university training business revenue increased by approximately 30% year-on-year, while high school training revenue grew by about 21% year-on-year [1][5]. - The new education business revenue increased by 49.8% year-on-year, driven by non-academic training and learning machine subscriptions, which reached 323,000 users, up 78.5% year-on-year [1][5]. Future Outlook - The company projects FY2025-2027 revenue forecasts of $5.113 billion, $6.414 billion, and $7.893 billion, respectively, with Non-GAAP net profits of $528 million, $796 million, and $1.096 billion, respectively [2][5]. - The overall education industry remains in a high-growth phase, with a persistent supply-demand imbalance for quality offerings, supporting the company's upward profit margin trajectory [2][5].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company's main brand experienced a slowdown in sales growth in Q3, but the overall performance remains positive with improvements in online and offline sales due to consumer promotion policies [1][2] - The subsidiary brand, Saucony, continues to show strong growth, with retail sales increasing by over 50% year-on-year [1] - The company is expected to benefit from the gradual divestment of non-core businesses, which will enhance overall profitability [1] Financial Performance Summary - **Revenue Forecasts**: - 2023A: 14,346 million - 2024E: 14,977 million (growth rate: 4%) - 2025E: 15,225 million (growth rate: 2%) - 2026E: 16,634 million (growth rate: 9%) [1][2] - **Net Profit Forecasts**: - 2023A: 1,030 million - 2024E: 1,254 million (growth rate: 22%) - 2025E: 1,352 million (growth rate: 8%) - 2026E: 1,542 million (growth rate: 14%) [1][2] - **Earnings Per Share (EPS)**: - 2023A: 0.39 - 2024E: 0.47 - 2025E: 0.51 - 2026E: 0.58 [1][2] - **Price-to-Earnings (P/E) Ratio**: - 2023A: 13.4 - 2024E: 11.0 - 2025E: 10.2 - 2026E: 9.0 [1][2] - **Price-to-Book (P/B) Ratio**: - 2023A: 1.6 - 2024E: 1.3 - 2025E: 1.2 - 2026E: 1.0 [1][2] Market Position and Strategy - The company is focusing on a multi-brand strategy, with the main brand concentrating on the running segment, which has shown significant improvements in product, brand, and channel strength [1] - The company plans to enhance the Saucony brand's market presence by expanding its franchise channels [1] - The overall discount control remains healthy, with a retail discount of approximately 25% [1]

Investment Rating - The report assigns a "Buy" rating for the company, Xinda Biopharma (01801.HK), marking its first coverage [2][6]. Core Insights - Xinda Biopharma has established itself as a comprehensive biopharma entity with significant commercialization achievements. The company is expected to reach a profitability inflection point as new products continue to receive approvals [3][4]. - The company has a robust pipeline in oncology, particularly focusing on IO+ADC strategies, with promising data emerging from its self-developed products [3][4]. - In non-oncology areas, the company is advancing treatments for obesity and Type 2 Diabetes Mellitus (T2DM), with major products expected to be approved within 1-2 years, providing new growth momentum [3][4]. - Overall, the company is viewed as undervalued in the market, with strong growth potential as a leading innovative drug company [3][4]. Summary by Sections Company Overview - Founded in August 2011, Xinda Biopharma has become a significant player in the biopharma sector, with 11 commercialized products and several others in various stages of clinical development [18][19]. - The company has established strategic partnerships with major international firms, enhancing its research and development capabilities [18][19]. Oncology Pipeline - The company has a deep focus on the oncology pipeline, with its PD-1 monoclonal antibody, Sintilimab, achieving nearly 2.8 billion yuan in sales in 2023, leading the domestic market [3][4]. - The PD-1/IL-2 dual antibody, IBI363, shows significant efficacy in PD-1 resistant cancer patients, positioning it as a potential leader in second-generation IO therapies [3][4]. - Multiple ADCs are in clinical stages, including IBI343 targeting CLDN18.2, which is in Phase III trials [3][4]. Cardiovascular and Metabolic Pipeline - The GLP-1 dual-target product, Masitide, is progressing well, with NDAs submitted for obesity and T2DM treatments, indicating a substantial market opportunity [3][4]. - The company has also received approval for its PCSK9 monoclonal antibody, marking a significant milestone in treating high cholesterol [3][4]. Autoimmune and Ophthalmology Pipeline - The company is expanding its autoimmune and ophthalmology product lines, with several innovative drugs entering clinical trials [3][4]. - Notable products include IBI302 for age-related macular degeneration and IBI112 for plaque psoriasis, both showing promising clinical data [3][4]. Financial Projections and Valuation - Revenue projections for 2024-2026 are estimated at 80.19 billion, 108.53 billion, and 139.04 billion yuan, with growth rates of 29.22%, 35.34%, and 28.11% respectively [4][6]. - The company is expected to achieve profitability by 2025, with a reasonable equity value estimated at 966.1 billion yuan, corresponding to a target stock price of 64.91 HKD [4][6].

Investment Rating - The report maintains a "Buy" rating for the company, with a target price of 24.95 HKD based on a 19x valuation for 2024 [2][7]. Core Insights - The company reported a decline in revenue for Q3 2024, with overall sales for the Li Ning brand experiencing a mid-single-digit percentage decrease compared to the previous half-year. Offline channels saw a high single-digit decline, while e-commerce channels achieved mid-single-digit growth [1]. - As of September 30, 2024, the number of sales points in China reached 6,281, a net increase of 42 from the previous quarter. This includes a net decrease of 14 in retail and a net increase of 55 in wholesale [1]. - The establishment of a joint venture with Sequoia to expand into international markets is noted, with the company investing 5.8 million HKD for a 29% stake. The financial impact of this venture is expected to be limited, with a payment of 58 million HKD in Q4 [1]. - Despite the pressure on retail revenue, the company is expected to manage inventory effectively and maintain a low double-digit net profit margin for the year, supported by strict cost control [1]. Financial Forecast and Ratios - The earnings per share (EPS) estimates for 2024-2026 have been adjusted to 1.20, 1.37, and 1.54 CNY, down from previous estimates of 1.24, 1.47, and 1.69 CNY [2][7]. - The company’s projected revenue for 2024 is 25,803 million CNY, with a growth rate of 2.4%, followed by 7.6% and 8.6% in subsequent years [5]. - The gross margin is expected to improve slightly from 48.4% in 2023 to 49.2% in 2024, while the net margin is projected to decrease from 11.5% to 11.0% [5].

Investment Rating - The report maintains a "Buy" rating for the company [3] Core Views - The company experienced a revenue decline of 7.9% year-on-year in FY2025H1, with a net profit drop of 34.7% to 870 million RMB, attributed to a challenging consumer environment and increased terminal discounts [1] - Despite short-term performance pressures, the company continues to implement a high dividend strategy, declaring an interim dividend of 0.14 RMB per share, resulting in a dividend payout ratio of 99% and a dividend yield of 5.4% based on the closing price on October 23 [1] - The company is expanding its brand partnerships and optimizing its store structure to ensure long-term growth, including becoming the exclusive operator for the high-end outdoor brand Norda in China [1][2] Revenue and Profitability - For FY2025H1, the company's revenue was 13.055 billion RMB, with a gross margin of 41.1%, down 3.6 percentage points year-on-year [1] - The company's retail and wholesale businesses both saw declines, with wholesale revenue down 2.2% to 2.04 billion RMB and retail revenue down 8.9% to 10.92 billion RMB [2] - The company anticipates a further revenue decline in FY2025, projecting a nearly 40% drop in net profit due to ongoing market uncertainties [6] Business Model and Strategy - The company is focusing on enhancing its online presence, with over 2,500 stores opening mini-programs and a 200% increase in sales through Douyin live streaming, making it the top player in the outdoor sports category on the platform [2] - The company has increased its membership base to 81 million, with member sales accounting for 93.7% of total sales, indicating strong consumer loyalty [2] Financial Forecast - The company’s revenue is projected to decline to 26.523 billion RMB in FY2025, with net profit expected to drop to 1.337 billion RMB [10][14] - The report adjusts the net profit forecasts for FY2025 to FY2027 to 1.337 billion RMB, 1.476 billion RMB, and 1.639 billion RMB respectively, with a corresponding P/E ratio of 12 times for FY2025 [6][10]

Investment Rating - The report assigns a "Buy" rating for the company, Shenzhou International, as it is a leading player in the global sportswear manufacturing industry [2][43][44] Core Insights - Shenzhou International has a strong competitive advantage due to its long-standing relationships with high-quality clients, mature manufacturing technology, and diversified production capacity [2][4][44] - The company is expected to benefit from the ongoing recovery in the global sportswear market, with significant growth potential driven by overseas replenishment and expansion of production capacity [2][4][44] - The report forecasts that the company's net profit will grow from 5.785 billion RMB in 2024 to 7.488 billion RMB in 2026, representing year-on-year growth rates of 26.93%, 14.57%, and 12.98% respectively [2][4][42] Summary by Sections 1. Company Overview - Shenzhou International, established in 1988, has developed a robust client base and is a key supplier for major brands like Uniqlo, Nike, and Adidas [9] - The company has a production capacity exceeding 25 million tons of fabric and 550 million garments annually, with a workforce of approximately 97,000 employees [9] 2. Client Demand and Market Trends - The global sportswear market is experiencing growth, particularly in emerging markets, which is expected to continue [15] - The report highlights that the replenishment cycle for inventory among downstream brands is contributing positively to order volumes [15] 3. Competitive Advantages - Shenzhou International's scale and efficiency place it at the forefront of the industry, with high employee productivity and a strong return on equity (ROE) [2][4][25] - The company has maintained a stable gross margin and net profit margin, indicating effective cost management [12][28] 4. Financial Projections - Revenue is projected to increase from 27.954 billion RMB in 2024 to 34.665 billion RMB in 2026, with corresponding growth rates of 11.94%, 11.80%, and 10.90% [42][41] - The report anticipates that the company's sales and management expense ratios will improve, further enhancing profitability [41][39] 5. Valuation Comparison - Shenzhou International's price-to-earnings (P/E) ratio for 2024 is estimated at 15.7x, which is lower than the average P/E of comparable companies at 21.3x, indicating a favorable valuation [2][44]

Investment Rating - The report maintains a "Recommended" rating for the company, indicating an expectation to outperform the benchmark index by 10%-20% over the next six months [1][16]. Core Insights - The company has shown a steady increase in financing amounts, with a total facilitated financing of 270.84 billion yuan in Q1-Q3 2024, representing a year-on-year growth of 17.4%. The gross profit margin has significantly improved in Q3 [1]. - The company operates primarily on a SaaS service model, charging a fee based on a percentage of the facilitated financing amount, which is a key factor influencing revenue [1]. - The report highlights a comprehensive growth in customer numbers and a high customer retention rate of 96% as of Q3 2024 [1]. Summary by Sections Financing Performance - Total facilitated financing for Q1-Q3 2024 reached 2708.39 billion yuan, up 17.4% year-on-year. The breakdown includes: - Electronic debt certificate business: 1752.4 billion yuan (up 16.7% year-on-year), accounting for 65% of total financing. - Asset securitization business: 797.8 billion yuan (up 11.9% year-on-year), representing 29% of total financing. - Cross-border cloud financing: 149.1 billion yuan (up 66.8% year-on-year), accounting for 6% of total financing [1]. Customer Growth - As of Q3 2024, the company has partnered with 1917 core enterprises (up 28.8% from the beginning of the year) and 353 financial institutions (up 11.0%). The number of core enterprise customers reached 821 (up 35.9%) [1]. Financial Projections - The report projects adjusted EPS for 2024, 2025, and 2026 to be -0.12, -0.01, and 0.06 yuan respectively, with corresponding sales per share (SPS) of 0.40, 0.47, and 0.58 yuan. The target price is set at 2.07 HKD based on a 4x PS valuation for 2025 [1][2].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 9.78, based on an 18x valuation for 2024 [2][7]. Core Insights - The company is positioned in the lucrative spicy snack food sector, with a compound annual growth rate (CAGR) of approximately 22.6% expected for net profit from 2024 to 2026. The market for flavored noodle products is anticipated to see accelerated market share growth, while konjac products are entering a period of significant growth [2][7]. - The report highlights the company's strong brand recognition and innovative product development capabilities, which are expected to drive continued revenue growth and market expansion [5][20]. Summary by Sections Strategic Positioning - The company has established itself as a leading brand in the spicy snack food market, benefiting from a significant reduction in low-priced products, with the share of products priced below 1 yuan dropping from 81% to 8% over the past decade. This positions the company to potentially increase its market share to over 30% [1][20]. - The konjac product segment is experiencing explosive growth, with a market size exceeding 2 billion yuan, and the company is well-positioned to capitalize on this expansion [1][20]. Product and Channel Development - The company focuses on two core product lines: spicy snacks and vegetable products, with a strong emphasis on product innovation and brand reinforcement. The spicy snack segment, particularly the "spicy strips," remains a solid foundation for growth, while vegetable products are emerging as a significant growth driver [1][20]. - The company is expanding its distribution network, aiming for 1 million offline terminals, and has seen a doubling of its presence in snack wholesale and Douyin channels compared to the previous year [1][20]. Financial Performance - The company's revenue has shown steady growth, with a projected increase from 48.72 billion yuan in 2024 to 77.04 billion yuan by 2026, reflecting a growth rate of 12.85% [3][20]. - The net profit attributable to the parent company is expected to rise from 8.80 billion yuan in 2024 to 16.23 billion yuan in 2026, with a remarkable growth rate of 481.87% in 2024 [3][20]. Market Trends - The spicy snack food market is expected to grow significantly, with the overall market size projected to reach 697 billion yuan by 2026. The report emphasizes the distinct characteristics of spicy snacks, which cater to younger consumers and have a high repurchase rate [1][30]. - The report notes that the flavored noodle product segment is experiencing a surge in demand, driven by consumer preferences and market cultivation efforts, which are expected to lead to substantial market expansion [1][30].

Investment Rating - The report maintains a "Buy" rating for Li Ning (2331) [2] Core Views - Q3 sales met expectations, with healthy discount inventory and strong National Day sales performance [2] - Q4 sales are expected to improve significantly due to a low base effect [2] - Long-term growth is supported by brand strength, product innovation, and refined operations [2] - Overseas business is promising with the establishment of a joint venture with Sequoia [2] Financial Performance - Q3 total channel sales declined by mid-single digits year-over-year, with offline sales down by high single digits and online sales up by mid-single digits [2] - Terminal discounts deepened, with offline discounts increasing by low single digits year-over-year [2] - Inventory-to-sales ratio was approximately 5 months as of September, with a healthy inventory age structure [2] - National Day sales showed improvement both online and offline, with positive sales growth since October [2] - Full-year 2024 revenue growth is expected to be low single digits, with a low double-digit profit margin [2] Joint Venture and Overseas Expansion - Li Ning established a joint venture with Sequoia to develop and operate the Li Ning brand outside mainland China [2] - The listed company and Mr Li Ning hold a combined 55% stake in the joint venture, with an investment of approximately HKD 58 million [2] - The joint venture is expected to accelerate the brand's internationalization with Sequoia's resources and expertise [2] - The listed company has the right to reclaim partial equity after 4 years and full equity after 8 years, ensuring control over overseas operations [2] Financial Forecasts - Net profit forecasts for 2024-2026 are maintained at RMB 3 20 billion, RMB 3 62 billion, and RMB 3 88 billion, respectively [2] - Corresponding P/E ratios are 12x, 11x, and 10x for 2024-2026 [2] Market Data - Current stock price: HKD 15 28 [2] - 52-week price range: HKD 12 92 - HKD 30 20 [3] - Current market capitalization: HKD 39 491 million [3] Peer Comparison - Li Ning's 2024E P/E ratio is 13x, compared to the peer average of 12x [6] - 2024E EPS is HKD 1 14, with 2025E and 2026E EPS at HKD 1 29 and HKD 1 39, respectively [6]